Forward Industries, Inc. (FORD) - 10-Q Summary
Business Context and Reporting Period
Company: Forward Industries, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: A global design company providing hardware and software product design and engineering services to medical and technology customers. Following the exit of its retail distribution segment (2023) and the sale of its OEM distribution segment (May 2025), the Company now operates solely as a design segment.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Nine Months Ended June 30, 2025 |
|---|---|---|
| Net Revenues (Continuing Ops) | $2.49 million | $10.24 million |
| Gross Profit/(Loss) | $(0.62) million | $0.33 million |
| Operating Loss | $(2.56) million | $(5.28) million |
| Net Loss (Continuing Ops) | $(2.40) million | $(5.12) million |
| Net Loss (Total, incl. Discontinued) | $(0.85) million | $(3.01) million |
| Cash and Equivalents | $1.26 million (June 30, 2025) | $5.60 million (Aug 12, 2025) |
| Working Capital | $1.21 million | N/A |
| Accumulated Deficit | $(22.65) million | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Continuing operations revenue dropped 50.5% quarter-over-quarter (Q3 2025 vs. Q3 2024) and 32.8% year-to-date. This is primarily due to the loss of a major customer's insulin patch pump program in December 2024 and reduced project volume.
- Margin Compression: Gross margin turned negative in Q3 2025 (-24.9%) compared to 26.0% in Q3 2024, driven by lower utilization rates and fixed costs.
- Discontinued Operations: The Company sold its OEM segment in May 2025, resulting in a one-time gain of approximately $1.41 million, which significantly offset the net loss for the quarter.
- Goodwill Impairment: A $225,000 goodwill impairment charge was recorded in Q4 2024 (included in the nine-month period) related to the IPS reporting unit due to the loss of the major customer. No further impairment was recorded in Q3 2025.
- Related Party Transactions: The Company converted $4.925 million of accounts payable to Forward China (related party) into Series A-1 Convertible Preferred Stock to satisfy debt and maintain Nasdaq compliance.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern for the 12 months following the filing date due to accumulated deficits and forecasted cash flow needs.
- Liquidity Strategy: The Company recently raised capital through a $1 million Series B Preferred Stock issuance (May 2025), a $35 million Equity Line of Credit (ELOC), and a registered direct offering ($2.23 million in August 2025). As of the filing date, all shares registered under the ELOC had been sold.
- Customer Concentration: Revenue remains highly concentrated; two customers represented 32.4% of revenue in Q3 2025.
- Market Risks: Global tariff uncertainties have caused customers to delay project commitments, impacting revenue visibility.
- Management Changes: Terence Wise, former CEO and Chairman, resigned in May 2025 in connection with the sale of the OEM segment.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.6 million cash balance (as of Aug 12, 2025) against the "substantial doubt" going concern warning and upcoming debt maturities (e.g., $600k note to Forward China due Dec 31, 2025).
- Revenue Recovery: Assess the pipeline for new design projects to replace the lost insulin patch pump revenue, which represented >30% of FY2024 revenue.
- Dilution Impact: Review the terms of the Series B Preferred Stock (10% dividend, conversion at $4.50) and the ELOC to understand potential dilution to common shareholders.
- Debt Obligations: Confirm the status of the $450,000 "Due to Forward China" and the scheduled payments of $150,000 each in July, August, and September 2025 related to the OEM sale.
- Warrant Liability: Monitor the fair value of the warrant liability ($402,888 at June 30, 2025), as fluctuations impact net income/loss.